**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 4724**

**Columns: META-ANALYSIS**

Association of interleukin-10 polymorphisms with irritable bowel syndrome risk: A meta-analysis

Qin SY *et al*. IL-10 polymorphisms and IBS risk

Shan-Yu Qin, Hai-Xing Jiang, Dong-Hong Lu, You Zhou

**Shan-Yu Qin, Hai-Xing Jiang, Dong-Hong Lu,** Department of Gastroenterology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**You Zhou,** Minerva Foundation Institute for Medical Research, FI-00290 Helsinki, Finland

**Author contributions:** Qin SY and Zhou Y conceived the study and implemented the final draft of the manuscript; Jiang HX and Lu DH performed the statistical analysis and wrote the paper; Qin SY and Lu DH searched the studies and extracted the data. All authors read and approved the final manuscript.

**Supported by** National Natural Science Foundation, No. 81260083; 31360221

**Correspondence to: You Zhou, MD, PhD,** Minerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, FI-00290, Helsinki, Finland. zhouchin123@163.com

**Telephone:** +358-9-19125711 **Fax:** +358-9-19125701

**Received:** July 18, 2013  **Revised:** September 18, 2013

**Accepted:** October 19, 2013

**Published online: Abstract**

**AIM:** To clarify the current understanding of the association between interleukin-10 (IL-10) polymorphisms and the risk of irritable bowel syndrome (IBS).

**METHODS:** We searched for studies in any language recorded in PubMed, Embase and Cochrane library before August 2013. The associations under allele contrast model, codominant model, dominant model, and recessive model were analyzed respectively. The strengths of the association between IL-10 polymorphisms and IBS risk were estimated by odds ratios (OR) with 95%CI. Fixed effects model would be used to pool the result if the test of heterogeneity was not significant, otherwise the random-effect model would be selected.

**RESULTS:** Eight case-control studies involving in 928 cases and 1,363 controls analyzing three SNPs rs1800870 (-1082 A/G), rs1800871 (-819C/T), and rs1800872 (-592A/C) of IL-10 gene were eligible for our analysis. The results showed that rs1800870 polymorphisms were associated with decreased risk of IBS (GG+GA *vs* AA: OR = 0.80, 95%CI: 0.66-0.96), (AA+GA *vs* GG: OR = 0.68, 95%CI: 0.52-0.90). Subgroup analysis revealed such association only existed in Caucasian ethnicity (AA+GA *vs* GG, OR = 0.70, 95%CI: 0.55-0.89). The rs1800872 polymorphisms were associated with an increased risk of IBS in Asian ethnicity (CC *vs* GG: OR = 1.29, 95%CI: 1.01-1.16). There were no associations between rs1800871 polymorphisms and the IBS risk. No publication bias was found (all *P* > 0.05)

**CONCLUSIONS:** The results suggest that IL-10 rs1800870 is conferred susceptibility to the risk of IBS in Caucasian ethnicity, and the rs1800872 may associate with IBS risk in Asians. However, no significant associations are found between rs1800871 and IBS risk.

© 2013 Baishideng. All rights reserved.

**Key words:** Interleukin-10; Irritable bowel syndrome; Gene polymorphism; Case-control; Meta-analysis

**Core tip:** Interleukin-10 (IL-10) polymorphisms have been identified as a biomarker causally associated with occurrence of irritable bowel syndrome (IBS) and receives extensive interest. However, its relationship with IBS remains obscure. In this paper, after combing the data from 8 case-control studies with 928 cases and 1,363 controls, the authors found that the IL-10 rs1800870 is conferred susceptibility to the risk of IBS in Caucasian ethnicity, and the rs1800872 may associate with IBS risk in Asians. However, no significant associations are found between rs1800871 and IBS risk.

Qin SY, Jiang HX, Lu DH, Zhou Y. Association of interleukin-10 polymorphisms with irritable bowel syndrome risk: A meta-analysis.

**Available from: URL:**

**DOI:**

**Introduction**

Irritable bowel syndrome (IBS) is a type of functional gastrointestinal disorder that has a multi-factorial origin. The exact pathophysiology leading to the occurrence of IBS is largely unknown, although inflammatory reactions are believed to play an important role in its pathogenesis. In some animal studies, researchers have found that inflammatory responses can alter the function of gut smooth muscles, enteric nerves, and interstitial cells of Cajal[1-3]. Moreover, IBS patients show an increase in the number of inflammatory cells in the gut[4-6]. The clustering of IBS in families and the results from twin studies have also provided evidence for a role of hereditary factors in the propensity of developing IBS[7, 8].

Cytokines are important modulators of immune responses and inflammatory reactions and play a central role in intestinal inflammation[9]. Thus, the production of cytokines could be affected by genetic polymorphisms within the coding and promoter regions of cytokine genes[10, 11]. Therefore, a genetic predisposition for the high or low production of a particular cytokine may affect disease susceptibility and clinical outcome[12, 13]. Interleukin 10 (IL-10), also known as a human cytokine synthesis inhibitory factor, is an anti-inflammatory cytokine capable of inhibiting the synthesis of proinflammatory cytokines, such as interferon-γ, IL-2, IL-3, and tissue necrosis factor-α, which are produced by macrophages and regulatory T-cells[14]. Several studies have shown that serum IL-10 levels are significantly lower in IBS patients than in normal controls, suggesting that altered IL-10 levels may be involved in the pathogenesis of IBS and may be an IBS biomarker[15-17].

Some reports[18-21] have also indicated a significant association between IL-10 polymorphisms and IBS risk; however, other studies[13, 22-24] have failed to find such associations. Generally, this disparity may be partly due to ethnic differences or to the limited numbers of subjects involved in the studies. Therefore, the relationship between IBS risk and IL-10 polymorphism is not confirmed and needs further study in a large, genetically homogenous sample. The current study is a comprehensive meta-analysis performed to further evaluate the associations between IL-10 polymorphisms and the risk of IBS.

**MATERIALS AND METHODS**

***Search strategy and study selection***

All methods were based on the guidelines proposed by the Human Genome Epidemiology Network for systematic reviews of genetic association studies, and followed the PRISMA guidelines[25]. A systematic literature search was performed using PubMed, Embase, the Cochrane Library, Google Scholar databases, Chinese National Knowledge Infrastructure (CNKI), and conference abstracts to identify published genetic association studies evaluating IL-10 polymorphisms and IBS risk published prior to August 2013; letters and abstracts were included. The Medical Subject Headings and text words used for the search were “interleukin-10” or “IL-10”, “polymorphism,” and “irritable bowel syndrome” or “IBS”. Search results were limited to human studies. All languages were searched, and the retrieved articles were translated, when necessary. The references of the identified publications were searched for additional studies, and the MEDLINE option for searching for related articles was used to examine all relevant articles.

***Inclusion and exclusion criteria***

Studies were included if (1) they examined the association between IL-10 polymorphisms and IBS risk; (2) had a case–control design; and (3) contained sufficient information on genotype frequency. To achieve adequate statistical power, only single-nucleotide polymorphisms (SNPs) reported in >2 publications were selected. For studies describing results from the same or overlapping groups of subjects or controls, but reported in >1 publication, only the largest published data set was included.

Studies were excluded if they did not evaluate the association between IL-10 polymorphisms and the risk of IBS or if the genotype and allele frequency was inadequately reported, and such data could not be obtained by contacting the authors. Studies reporting associations with SNPs described by fewer than 3 publications were also excluded. In the event of duplicate publications, the smaller data set was excluded.

***Data extraction***

Two investigators independently extracted data from the identified publications, including the first author’s name, year of publication, source of publication, IBS diagnosis criteria, method of genotyping, number of cases and controls, genotype frequency, and allele frequency. Discrepancies in data extraction were resolved by repeating the study review and discussing the results.

***Statistical analysis***

Associations found with the allele contrast, codominant, dominant, and recessive models were analyzed. The strengths of the associations between IL-10 polymorphisms and risk of IBS were estimated using odds ratios (OR), with 95%CI. We assessed the heterogeneity among the studies using the Cochran’s Q-test. We also calculated the inconsistency index I2 to quantify heterogeneity[26]. A fixed effects model (*P* > 0.05) was used to pool the results if a heterogeneity test was not significant, otherwise a random-effects model was used (*P* < 0.05)[27, 28]. Subgroup analyses were performed to investigate narrower subsets of studies.

A Hardy-Weinberg equilibrium (HWE) was applied to the control population to evaluate data quality. The HWE analysis for genotype distribution among control populations was performed using a Chi-squared test. Further, a sensitivity analysis was performed to exclude studies that were not in HWE[29]. An asymmetric plot was used to suggest possible publication biases. Publication bias was examined using the Begg’s and Egger’s tests for each SNP publication[30, 31]. All statistical tests were two-sided, and a *P* value < 0.05 was considered statistically significant. STATA, version 11.2 (Stata, College Station, TX, United States), was used for all statistical analyses.

**Results**

***Study selection process***

The initial search yielded 28 studies; 15 were excluded because they were review articles, animal studies, or non-case-control design studies. After screening the full text of the remaining 13 studies, an additional 5 studies were excluded; of these, 4 explored SNPs reported by < 3 studies and one[19] did not provide sufficient genotype frequency data, even after contacting the original authors. Thus, a total of 8 case-control studies[18-24, 32], involving 928 cases and 1363 controls, were included in the present meta-analysis. The studies analyzed 3 IL-10 SNPs, rs1800870 (1082 A/G), rs1800871 (819 C/T), and rs1800872 (592 A/C). Figure 1 provides a summary of the selection process.

***Characteristics of included studies***

One study selected IBS patients using the Rome I criteria, 3 used the Rome II criteria, and the other 4 studies used the Rome III criteria. Patients from 4 studies[18-21] were Caucasians, and 4 studies involved Asians[22-24, 32]. The characteristics of the 8 studies and the results of the HWE test for the distribution of the genotype in the control population are shown in Table 1.

***IL-10 rs1800870 and IBS risk***

Seven studies[13, 18, 20-24], involving 616 IBS subjects and 1038 controls, analyzed the association between the IL-10 rs1800870 polymorphism and IBS risk. The distribution of the controls in 2 studies[20, 21] deviated from the HWE. Overall, the GG+GA *vs* AA (OR = 0.80; 95%CI: 0.66–0.96; *P* = 0.018) and AA+GA *vs* GG (OR = 0.68; 95%CI: 0.52–0.90; *P* = 0.007) models presented a decreased risk of IBS. Little heterogeneity was found in the AA+GA *vs* GG model (*I*2 = 0.0%; *P* = 0.542) by the *I*2 test and Q-test; however, there was significant heterogeneity in the GG+GA *vs* AA (*I*2 = 79.4%, *P* = 0.000) model. There were no significant associations between the GG *vs* AA (*P* = 0.523) and G *vs* A (*P* = 0.892) models and IBS risk. Egger’s and Begg’s tests suggested little publication bias in the 4 models (all, *P* > 0.05) (Table 2, Figure 2A). In the sensitivity analysis, after removing 2 studies[[20](#_ENREF_20), [21](#_ENREF_21)] in which the controls deviated from the HWE, significant associations with the GG+GA *vs* AA model were no longer observed, and the heterogeneity became negligible (data not shown); the associations remained for the AA+GA *vs* GG (OR = 0.69; 95%CI: 0.52–0.91; *P* = 0.008) model. Subgroup analysis revealed associations between the IL-10 rs1800870 polymorphisms and IBS risk in Caucasians[[18](#_ENREF_18" \o "Barkhordari, 2010 #19), [20](#_ENREF_20), [21](#_ENREF_21)] (*P* = 0.003), but not in Asians[22-24] (*P* = 0.860) (Table 2).

***IL-10 rs1800871 and IBS risk***

Four studies[18, 20, 23, 24], involving 493 IBS subjects and 663 controls, analyzed the associations between the IL-10 rs1800871 polymorphisms and IBS risk; the distribution of controls in the studies fulfilled the HWE. In the meta-analysis, no significant associations were observed for any of the 4 models: AA *vs* GG (*P* = 0.698), AA+AG *vs* GG (*P* = 0.969), GG+AG *vs* AA (*P* = 0.651), and A *vs* G (*P* = 0.496). Either significant heterogeneity or publication bias was found associated with each of the 4 models (all, *P* > 0.05). A sensitivity analysis, after excluding studies in turn, indicated that the null associations remained (data not shown). Further, subgroup analyses did not find any associations between the IL-10 rs1800871 polymorphisms and IBS risk, regardless of ethnicity[18, 20, 23, 24] (Table 3, Figure 2B).

***IL-10 rs1800872 and IBS risk***

Five studies[18, 20, 23, 24, 32], involving 181 IBS subjects and 338 controls, analyzed the associations between IL-10 rs1800872 polymorphisms and IBS risk; the distribution of the controls in the studies fulfilled the HWE. The meta-analysis demonstrated that the CC+CA *vs* AA model was associated with a susceptibility to IBS risk (OR = 1.29, 95%CI: 1.03–1.62, *P* = 0.028). However, significant associations were not found between the other 3 models, CC *vs* AA (*P* = 0.989), AA+CA *vs* CC (*P* = 0.833), and C *vs* A (*P* = 0.112), and IBS risk. Either significant heterogeneity or publication bias was found in each of the 4 models (all, *P* > 0.05). A sensitivity analysis, after removing each study sequentially, demonstrated that the results remained similar to the initial results. Subsequent subgroup analyses showed associations between rs1800872 and IBS risk in Asians[23, 24, 32] (*P* = 0.042), but not in Caucasians[18, 20] (*P* = 0.417) (Table 4, Figure 2C).

**Discussion**

The gene encoding IL-10 is located on chromosome 1q31–1q32, and has 3 confirmed biallelic polymorphisms in the gene promoter region, i.e., rs1800870, rs1800871, and rs1800872. A genetic predisposition for low IL-10 production is associated with the development of IBS[33-35], and previous studies have shown that IL-10 SNPs and some haplotypes are associated with an increased IBS risk[5, 13, 18, 23]. Likewise, production of the anti-inflammatory cytokine IL-10 is also associated with SNPs at specific positions.

The A allele of rs1800870 has been reported to be associated with lower production of IL-10 and an accordingly stronger inflammatory response[36]. More recently, Bashashati *et al*[37] reported the results of a meta-analysis that showed that the A/G of rs1800870 conferred susceptibility to IBS. However, their study only included 5 studies, and most of the included subjects were Caucasians. When considering the disparity in genetic factors among different racial groups, it is difficult to conclude that rs1800870 was associated with IBS risk, without adjusting for ethnicity and sample size. In the present study, although the overall meta-analysis results showed the presence of significant associations between rs1800870 and IBS risk in the GG+GA *vs* AA (*P* = 0.018) and AA+GA *vs* GG (*P* = 0.007) models. A subgroup analysis revealed that such association existed only for Caucasians, and not for Asians. This disparity between the two ethnicities might be explained by variations in allelic frequencies between the ethnic groups. This was possible since the frequency of the rs1800870 A allele is associated with a significantly higher production of IL-10 in Caucasians than in Asians. Moreover, another study showed that the frequency of the high producer IL-10 genotype is much higher in the Irish population than in Africans or Singaporean Chinese[38]. In the present study, 4[13, 18, 20, 21] of the 8 included studies analyzed Caucasian subjects, the frequency of the rs1800870 GG genotype in controls was higher than that observed in Asian subjects. The present meta-analysis results confirmed the association of rs1800870 and IBS risk, but also demonstrated that the association varies according to ethnicity.

The role of rs1800871 in IL-10 production is incompletely understood. Although some studies have reported that rs1800871 is associated with several diseases, such as endometriosis[39] and periodontitis[40], the association between rs1800871 and IBS has remained controversial[18, 20, 23, 24]. In our study, the overall results and the results of the subgroup analysis failed to show a significant association between rs1800871 and IBS risk, regardless of the examined ethnicity. This observation indicates a similar distribution of rs1800871 among both IBS patients and controls, supporting the observation that the genetic make-up for IL-10 production levels does not differ between IBS patients and normal subjects[13, 18, 24]. Although a direct link between rs1800871 and IL-10 production levels has not been established, previous reports have suggested that rs1800871 polymorphism is in linkage disequilibrium with rs1800871; that the haplotypes for rs1800870, rs1800871 and rs1800872 are common in Caucasians; and that the GCC/GCC haplotypes are commonly associated with high IL-10 production, whereas the ATA/ATA genotype is associated with low IL-10 production[41]. Because only limited data are available in the included studies, further studies may be required to perform a haplotype analysis to explore the associations between rs1800871 haplotypes and other SNPs with IBS.

With regard to rs1800872, studies have reported that the presence of rs1800872 confers susceptibility to some diseases such as leprosy[42] and hepatocellular carcinoma[43]. In studies investigating the association of IL-10 and IBS risk, Santhosh *et al*[23] reported that the C allele was much lower in individuals with IBS than among normal controls (41.3% *vs* 73.5%), in an Indian population. Wang *et al*[24] found similar results in a Chinese population (IBS *vs* controls, 9.3% *vs* 17.1%). However, a Mexican study[18] failed to show a significant difference between IBS patients and normal controls with respect to the C allele (72.51% *vs* 71.1%); similar results were reported in 2 other studies[19, 20]. In the present meta-analysis, we found that CC+CA *vs* AA was associated with an IBS risk, and the sensitivity analysis further confirmed this association. However, the subgroup analysis revealed that only Asians demonstrated this association. Although 5 studies were included in the present analysis, the sample size was relatively small; hence, these results should be interpreted with caution.

The present comprehensive meta-analysis demonstrated an association between rs1800871 and rs1800872 polymorphisms and IBS risk, and that the rs1800872 polymorphism conferred susceptibility to IBS. In addition, although Bashashati *et al*[37] reported a meta-analysis demonstrating that rs1800870 conferred susceptibility to IBS, we expanded this finding to show that this association existed in Caucasians but not in Asians, which had not been previously reported. The present study also involved a sensitivity analysis demonstrating that the distribution of controls deviated from the HWE, guaranteeing the reliability of the results. The Begg’s and Egger’s test results did not show a significant publication bias in the eligible as well as the non-English studies, which also attests to the robustness of the results.

Some limitations to this meta-analysis require careful consideration. First, because only limited data were available, we did not analyze the association between IL-10 polymorphisms and different types of IBS, e.g., diarrhea or constipation. Thus, the associations between different types of IBS require further investigation. Second, other factors such as genetic and environmental factors, which also may affect susceptibility to IBS, were not adjusted in the present studies. Hence, a well-designed study is warranted to account for potential confounders and to provide a more precise association. Third, also because of the limited number of available studies, the subgroup analysis of rs1800872 involved comparatively few studies; thus, its association with IBS needs to be confirmed by a study involving a larger number of subjects.

In conclusion, the present meta-analysis suggests that the rs1800870 polymorphism of IL-10 may represent an increased risk of IBS in Caucasians, but not in Asians. Similarly, rs1800872 polymorphisms may represent an increased risk of IBS in Asians, but future studies are necessary to reinforce these findings. The present study failed to find an association between rs1800871 and IBS risk, regardless of ethnicity.

**COMMENTS**

***Background***

Cytokines are important modulators in the immune responses and inflammatory reaction, which play a central role in intestinal inflammation.

***Research frontiers***

Interleukin-10 (IL-10) polymorphisms have been identified as a biomarker causally associated with occurrence of irritable bowel syndrome (IBS) and receives extensive interest. However, its relationship with IBS remains obscure.

***Innovations and breakthroughs***

This is the first paper conducting a comprehensive meta-analysis to investigate the association between IL-10 polymorphisms with IBS risk. The authors showed that IL-10 rs1800870 is associated with IBS risk in Caucasian ethnicity, and rs1800872 associate with IBS risk in Asians.

***Applications***

This study furthers the understanding of the association of IL-10 polymorphisms and IBS risk.

***Peer review***

The study deals with the important topic related to the association between single nucleotide polymorphisms of genes coding for inflammation-linked factors with pathogenesis of chronic inflammatory diseases such as IBS.

**References**

1 **Der T**, Bercik P, Donnelly G, Jackson T, Berezin I, Collins SM, Huizinga JD. Interstitial cells of cajal and inflammation-induced motor dysfunction in the mouse small intestine. *Gastroenterology* 2000; **119**: 1590-1599 [PMID: 11113080 DOI: S0016508500634224]

2 **Vallance BA**, Galeazzi F, Collins SM, Snider DP. CD4 T cells and major histocompatibility complex class II expression influence worm expulsion and increased intestinal muscle contraction during Trichinella spiralis infection. *Infect Immun* 1999; **67**: 6090-6097 [PMID: 10531271]

3 **Galeazzi F**, Haapala EM, van Rooijen N, Vallance BA, Collins SM. Inflammation-induced impairment of enteric nerve function in nematode-infected mice is macrophage dependent. *Am J Physiol Gastrointest Liver Physiol* 2000; **278**: G259-G265 [PMID: 10666050]

4 **Chadwick VS**, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. *Gastroenterology* 2002; **122**: 1778-1783 [PMID: 12055584 DOI: S0016508502000112]

5 **O'Sullivan M**, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the irritable bowel syndrome. *Neurogastroenterol Motil* 2000; **12**: 449-457 [PMID: 11012945 DOI: nmo221]

6 **Weston AP**, Biddle WL, Bhatia PS, Miner PB. Terminal ileal mucosal mast cells in irritable bowel syndrome. *Dig Dis Sci* 1993; **38**: 1590-1595 [PMID: 8359068]

7 **Levy RL**, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. *Gastroenterology* 2001; **121**: 799-804 [PMID: 11606493 DOI: S0016508501457933]

8 **Saito YA**, Zimmerman JM, Harmsen WS, De Andrade M, Locke GR, Petersen GM, Talley NJ. Irritable bowel syndrome aggregates strongly in families: a family-based case-control study. *Neurogastroenterol Motil* 2008; **20**: 790-797 [PMID: 18221250 DOI: 10.1111/j.1365-2982.2007.1077.x]

9 **Sartor RB**. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. *Gastroenterology* 1994; **106**: 533-539 [PMID: 8299918]

10 **Hoffmann SC**, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. *Transplantation* 2001; **72**: 1444-1450 [PMID: 11685118]

11 **Melk A**, Henne T, Kollmar T, Strehlau J, Latta K, Offner G, Jhangri GS, Ehrich JH, Von Schnakenburg C. Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children. *Kidney Int* 2003; **64**: 314-320 [PMID: 12787424 DOI: 10.1046/j.1523-1755.2003.00050.x]

12 **Hotoleanu C**, Popp R, Trifa AP, Nedelcu L, Dumitrascu DL. Genetic determination of irritable bowel syndrome. *World J Gastroenterol* 2008; **14**: 6636-6640 [PMID: 19034965]

13 **van der Veek PP**, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. *Am J Gastroenterol* 2005; **100**: 2510-2516 [PMID: 16279907 DOI: 10.1111/j.1572-0241.2005.00257.x]

14 **Maynard CL**, Weaver CT. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. *Immunol Rev* 2008; **226**: 219-233 [PMID: 19161427 DOI: 10.1111/j.1600-065X.2008.00711.x]

15 **Hua MC**, Lai MW, Kuo ML, Yao TC, Huang JL, Chen SM. Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome. *J Pediatr Gastroenterol Nutr* 2011; **52**: 376-381 [PMID: 21407110 DOI: 10.1097/MPG.0b013e3181fd9816]

16 **Schmulson M**, Pulido-London D, Rodriguez O, Morales-Rochlin N, Martinez-García R, Gutierrez-Ruiz MC, López-Alvarenga JC, Robles-Díaz G, Gutiérrez-Reyes G. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. *Am J Gastroenterol* 2012; **107**: 747-753 [PMID: 22270083 DOI: 10.1038/ajg.2011.484]

17 **Scully P**, McKernan DP, Keohane J, Groeger D, Shanahan F, Dinan TG, Quigley EM. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. *Am J Gastroenterol* 2010; **105**: 2235-2243 [PMID: 20407431 DOI: 10.1038/ajg.2010.159]

18 **Barkhordari E**, Rezaei N, Mahmoudi M, Larki P, Ahmadi-Ashtiani HR, Ansaripour B, Alighardashi M, Bashashati M, Amirzargar AA, Ebrahimi-Daryani N. T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome. *Inflammation* 2010; **33**: 281-286 [PMID: 20177758 DOI: 10.1007/s10753-010-9183-6]

19 **Olivo-Diaz A**, Romero-Valdovinos M, Gudiño-Ramirez A, Reyes-Gordillo J, Jimenez-Gonzalez DE, Ramirez-Miranda ME, Martinez-Flores WA, Martinez-Hernandez F, Flisser A, Maravilla P. Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican patient population with irritable bowel syndrome infected with Blastocystis. *Parasitol Res* 2012; **111**: 487-491 [PMID: 22287022 DOI: 10.1007/s00436-012-2830-0]

20 **Romero-Valdovinos M**, Gudiño-Ramírez A, Reyes-Gordillo J, Martínez-Flores WA, Ramírez-Miranda ME, Maravilla P, Olivo-Díaz A. Interleukin-8 and -10 gene polymorphisms in irritable bowel syndrome. *Mol Biol Rep* 2012; **39**: 8837-8843 [PMID: 22740130 DOI: 10.1007/s11033-012-1745-2]

21 **Gonsalkorale WM**, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? *Gut* 2003; **52**: 91-93 [PMID: 12477767]

22 **Lee HJ**, Lee SY, Choi JE, Kim JH, Sung IK, Park HS, Jin CJ. G protein beta3 subunit, interleukin-10, and tumor necrosis factor-alpha gene polymorphisms in Koreans with irritable bowel syndrome. *Neurogastroenterol Motil* 2010; **22**: 758-763 [PMID: 20337945 DOI: 10.1111/j.1365-2982.2010.01496.x]

23 **Santhosh S**, Dutta AK, Samuel P, Joseph AJ, Ashok Kumar J, Kurian G. Cytokine gene polymorphisms in irritable bowel syndrome in Indian population--a pilot case control study. *Trop Gastroenterol* ; **31**: 30-33 [PMID: 20860222]

24 **Wang BM**, Jiang XZ, Yang YL, Liu WT, Cao XC, Zhao XZ. [A study of interleukin-10 gene polymorphism in irritable bowel syndrome]. *Zhonghua Nei Ke Za Zhi* 2006; **45**: 289-292 [PMID: 16780675]

25 **Sagoo GS**, Little J, Higgins JP. Systematic reviews of genetic association studies. Human Genome Epidemiology Network. *PLoS Med* 2009; **6**: e28 [PMID: 19260758 DOI: 10.1371/journal.pmed.1000028]

26 **Higgins JP**, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]

27 **MANTEL N**, HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959; **22**: 719-748 [PMID: 13655060]

28 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188 [PMID: 3802833 DOI: 0197-2456(86)90046-2]

29 **Zintzaras E**, Rodopoulou P, Sakellaridis N. Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of stroke: a HuGE gene-disease association review and meta-analysis. *Am J Epidemiol* 2009; **169**: 523-532 [PMID: 19126581 DOI: 10.1093/aje/kwn368]

30 **Egger M**, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**: 629-634 [PMID: 9310563]

31 **Begg CB**, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994; **50**: 1088-1101 [PMID: 7786990]

32 **Jiang YJ**, Nie YQ, Lai XB. IL-10 gene promoter-592 polymorphism and irritable bowel syndrome. *Modern Hospital* 2010; **10**: 8-10

33 **Shah N**, Kammermeier J, Elawad M, Glocker EO. Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. *Curr Allergy Asthma Rep* 2012; **12**: 373-379 [PMID: 22890722 DOI: 10.1007/s11882-012-0286-z]

34 **Grundström J**, Linton L, Thunberg S, Forsslund H, Janczewska I, Befrits R, van Hage M, Gafvelin G, Eberhardson M. Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease. *Clin Exp Immunol* 2012; **169**: 137-147 [PMID: 22774988 DOI: 10.1111/j.1365-2249.2012.04600.x]

35 **Zhang W**, Yang AL, Liao J, Li H, Dong H, Chung YT, Bai H, Matkowskyj KA, Hammock BD, Yang GY. Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice. *Dig Dis Sci* 2012; **57**: 2580-2591 [PMID: 22588244 DOI: 10.1007/s10620-012-2217-1]

36 **Rad R**, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, Gerhard M, Prinz C. Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. *Gut* 2004; **53**: 1082-1089 [PMID: 15247172 DOI: 10.1136/gut.2003.029736]

37 **Bashashati M**, Rezaei N, Bashashati H, Shafieyoun A, Daryani NE, Sharkey KA, Storr M. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. *Neurogastroenterol Motil* 2012; **24**: 1102-e566 [PMID: 22897390 DOI: 10.1111/j.1365-2982.2012.01990.x]

38 **Meenagh A**, Williams F, Ross OA, Patterson C, Gorodezky C, Hammond M, Leheny WA, Middleton D. Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. *Hum Immunol* 2002; **63**: 1055-1061 [PMID: 12392859 DOI: S0198885902004408]

39 **Fan W**, Li S, Chen Q, Huang Z, Ma Q, Xiao Z. Association between interleukin-10 promoter polymorphisms and endometriosis: a meta-analysis. *Gene* 2013; **515**: 49-55 [PMID: 23237776 DOI: 10.1016/j.gene.2012.11.037]

40 **Albuquerque CM**, Cortinhas AJ, Morinha FJ, Leitão JC, Viegas CA, Bastos EM. Association of the IL-10 polymorphisms and periodontitis: a meta-analysis. *Mol Biol Rep* 2012; **39**: 9319-9329 [PMID: 22763734 DOI: 10.1007/s11033-012-1738-1]

41 **Turner DM**, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. *Eur J Immunogenet* 1997; **24**: 1-8 [PMID: 9043871]

42 **Cardona-Castro N**, Sánchez-Jiménez M, Rojas W, Bedoya-Berrío G. IL-10 gene promoter polymorphisms and leprosy in a Colombian population sample. *Biomedica* 2012; **32**: 71-76 [PMID: 23235789 DOI: 10.1590/S0120-41572012000100009]

43 **Wei YG**, Liu F, Li B, Chen X, Ma Y, Yan LN, Wen TF, Xu MQ, Wang WT, Yang JY. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. *World J Gastroenterol* 2011; **17**: 3941-3947 [PMID: 22025883 DOI: 10.3748/wjg.v17.i34.3941]

**P-Reviewers** **Filaci G, I**zzo AA  **S-Editor** Wen LL  **L-Editor**  **E-Editor**

**Figure 1 Flow chart of study selection.**

**Figure 2 Meta-analysis.** A: Interleukin-10 (IL-10) rs1800870 polymorphisms and IBS risk; B: IL-10 rs1800871 polymorphisms and IBS risk; C: IL-10 rs1800872 polymorphisms and IBS risk.

**Table 1 Characteristic of individual studies in the meta-analysis**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Year** | **Country/****Ethnicity** | **SNP of****IL-10** | **IBS/****Controls** | **Genotype Methods** | **Diagnosis****criteria** | **HWE****of control** |
| Gonsalkorale *et al*[21] | 2003 | United Kingdom | rs1800870 | 230/450 | PCR-SSP | Rome I | 0.000 |
| van der Veek *et al*[13] | 2005 | Netherlands | rs1800870 | 111/128 | PCR-RFLP | Rome II | 0.707 |
| Wang *et al*[24] | 2006 | China | rs1800870 | 43/41 | PCR-RFLP | Rome II | 0.678 |
| Barkhordari *et al*[18] | 2010 | Iran | rs1800870 | 70/140 | PCR-SSP | Rome III | 0.041 |
| Lee *et al*[22] | 2010 | South Korea | rs1800870 | 94/88 | PCR-RFLP | Rome III | 0.707 |
| Santhosh *et al*[23] | 2010 | Indian | rs1800870 | 23/20 | PCR-SSP | Rome II | 0.717 |
| Romero-Valdovinos *et al*[20] | 2012 | Mexico | rs1800870 | 45/173 | PCR-RFLP | Rome III | 0.000 |
|  |  |  |  |  |  |  |  |
| Wang *et al*[24] | 2006 | China | rs1800871 | 43/41 | PCR-RFLP | Rome II | 0.619 |
| Barkhordari *et al*[18] | 2010 | Iran | rs1800871 | 70/140 | PCR-SSP | Rome III | 0.907 |
| Santhosh *et al*[23] | 2010 | China | rs1800871 | 23/20 | PCR-SSP | Rome II | 0.662 |
| Romero-Valdovinos *et al*[20] | 2012 | Mexico | rs1800871 | 45/173 | PCR-RFLP | Rome III | 0.920 |
|  |  |  |  |  |  |  |  |
| Wang *et al*[24] | 2006 | China | rs1800872 | 43/41 | ARMS-PCR | Rome II | 0.619 |
| Barkhordari *et al*[18] | 2010 | Iran | rs1800872 | 70/140 | PCR-RFLP | Rome III | 0.970 |
| Jiang *et al*[32] | 2010 | China | rs1800872 | 312/325 | PCR-SSP | Rome III | 0.255 |
| Santhosh *et al*[23] | 2010 | Indian | rs1800872 | 23/20 | PCR-SSP | Rome II | 0.438 |
| Romero-Valdovinos *et al*[20] | 2012 | Mexico | rs1800872 | 45/173 | PCR-RFLP | Rome III | 0.018 |

SNP: Single nucleotide polymorphism; HWE: Hardy–Weinberg equilibrium; IBS: Irritable bowel syndrome.**Table 2 Summary odds ratios of rs1800870 polymorphisms with irritable bowel syndrome risk**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **rs1800870** | ***P*** | **OR(95%CI)** | ***I2*** | ***P*****heterogeneity** | **Begg’****test** | **Egger test** |
| GG *vs* AA | 0.338 | 1.11(0.89-1.39) | 0.0 | 0.950 | 1.000 | 0.694 |
| Caucasian[13,18,20,21] | 0.228 | 1.19(0.90-1.58) | 0.0 | 0.776 |  |  |
| Asian[22-24] | 0.963 | 1.01(0.71-1.42) | 0.0 | 0.999 |  |  |
|  |  |  |  |  |  |  |
| GG+GA *vs* AA | 0.018 | 0.80(0.66-0.96) | 79.4 | 0.000 | 1.000 | 0.200 |
| Caucasian | 0.003 | 0.70(0.55-0.89) | 88.5 | 0.000 |  |  |
| Asian | 0.860 | 1.03(0.74-1.43) | 0.0 | 0.990 |  |  |
|  |  |  |  |  |  |  |
| AA+GA *vs* GG | 0.007 | 0.68(0.52-0.90) | 0.0 | 0.542 | 1.000 | 0.899 |
| Caucasian | 0.008 | 0.69(0.52-0.91) | 0.0 | 0.415 |  |  |
| Asian | 0.478 | 0.31(0.01-7.76) | - | - |  |  |
|  |  |  |  |  |  |  |
| G *vs* A | 0.815 | 1.01(0.90-1.14) | 0.0 | 0.720 | 0.764 | 0.773 |
| Caucasian | 0.799 | 1.02(0.89-1.16) | 17.1 | 0.306 |  |  |
| Asian | 0.976 | 1.00(0.80-1.260 | 0.0 | 0.974 |  |  |

**Table 3 Summary odds ratios of rs1800871 polymorphisms with irritable bowel syndrome risk**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **rs1800871** | ***P*** | **OR(95%CI)** | ***I2*** | ***P*****heterogeneity** | **Begg’****test** | **Egger test** |
| AA *vs* GG | 0.698 | 0.90(0.53-1.54) | 0.0 | 0.440 | 0.308 | 0.326 |
| Caucasian[18,20] | 0.205 | 0.56(0.23-1.37) | 22.6 | 0.255 |  |  |
| Asian[23,24] | 0.530 | 1.25(0.62-2.54) | 0.0 | 0.969 |  |  |
|  |  |  |  |  |  |  |
| AA+GA *vs* GG | 0.969 | 0.99(0.61-1.60) | 32.4 | 0.218 | 0.308 | 0.146 |
| Caucasian | 0.182 | 0.58(0.26-1.29) | 0.0 | 0.365 |  |  |
| Asian | 0.252 | 1.45(0.77-2.76) | 0.0 | 0.364 |  |  |
|  |  |  |  |  |  |  |
| GG+GA *vs* AA | 0.651 | 0.92(0.64-1.33) | 0.0 | 0.720 | 0.734 | 0.080 |
| Caucasian | 0.985 | 1.00(0.68-1.49) | 0.0 | 0.906 |  |  |
| Asian | 0.219 | 0.54(0.20-1.45) | 0.0 | 0.967 |  |  |
|  |  |  |  |  |  |  |
| A *vs* G | 0.496 | 1.09(0.85-1.38) | 0.0 | 0.809 | 1.000 | 0.924 |
| Caucasian | 0.939 | 1.01(0.75-1.37) | 0.0 | 0.631 |  |  |
| Asian | 0.314 | 1.23(0.83-1.82) | 0.0 | 0.671 |  |  |

**Table 4 Summary odds ratios of rs1800872 polymorphisms with IBS risk**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **rs1800872** | ***P*** | **OR(95%CI)** | ***I2*** | ***P*****heterogeneity** | **Begg’****test** | **Egger test** |
| CC *vs* AA | 0.989 | 1.00(0.77-1.19) | 0.0 | 0.456 | 0.806 | 0.506 |
| Caucasian[18,20] | 0.379 | 0.73(0.37-1.47) | 41.6 | 0.191 |  |  |
| Asian[23,24,32] | 0.730 | 1.05(0.80-1.38) | 0.0 | 0.466 |  |  |
|  |  |  |  |  |  |  |
| CC+CA *vs* AA | 0.028 | 1.29(1.03-1.62) | 0.0 | 0.717 | 0.221 | 0.196 |
| Caucasian | 0.417 | 1.27(0.71-2.26) | 0.0 | 0.573 |  |  |
| Asian | 0.042 | 1.29(1.01-1.66) | 0.0 | 0.410 |  |  |
|  |  |  |  |  |  |  |
| AA+CA *vs* CC | 0.833 | 0.97(0.72-1.31) | 60.2 | 0.040 | 0.806 | 0.384 |
| Caucasian | 0.578 | 1.13(0.72-1.71) | 3.2 | 0.310 |  |  |
| Asian | 0.382 | 0.82(0.53-1.27) | 76.0 | 0.016 |  |  |
|  |  |  |  |  |  |  |
| C *vs* A | 0.112 | 1.12(0.97-1.28) | 0.0 | 0.863 | 0.086 | 0.266 |
| Caucasian | 0.614 | 1.12(0.97-1.28) | 0.0 | 0.669 |  |  |
| Asian | 0.114 | 1.14(0.97-1.33) | 0.0 | 0.618 |  |  |